title: Sensory gating deficits in psychiatric inpatients: relation to catecholamine metabolites in different diagnostic groups.
abstract: Acutely ill psychiatric inpatients were examined for a deficit in sensory gating, measured as failure to suppress the P50 wave of the auditory-evoked response to the second of paired stimuli. Previously, we had found that in mania, this sensory gating deficit is correlated with increased plasma-free levels of the noradrenergic metabolite 3-methoxy, 4-hydroxyphenylglycol (pMHPG), whereas in schizophrenia, there is no correlation with catecholamine metabolism. To assess the generalizability of these findings, we examined inpatients with a broader range of diagnoses, including those with multiple DSM III-R Axis I, II, and III diagnoses. The patients were grouped into three diagnostic spectra for analysis: schizophrenic, manic, and depressive. In the schizophrenic patients, there was no relationship between pMHPG or other catecholamine metabolites and the sensory gating deficit. In manic patients, however, a positive correlation between pMHPG level and the sensory gating deficit was again observed. This relationship did not extend to the depressive patients, who uniquely showed sensory gating deficits that correlated negatively with the severity of their illness. The data suggest that sensory gating deficits are common to these three diagnostic spectra, but the deficits in each group have different relationships to catecholamine metabolism and symptom severity that may reflect differences in the underlying neuronal pathophysiology of these illnesses.
authors.affiliation: Department of Psychiatry, University of Colorado Health Sciences Center, Denver 80262.
authors.forename: N J
authors.initials: NJ
authors.lastname: Baker
authors.forename: M
authors.initials: M
authors.lastname: Staunton
authors.forename: L E
authors.initials: LE
authors.lastname: Adler
authors.forename: G A
authors.initials: GA
authors.lastname: Gerhardt
authors.forename: C
authors.initials: C
authors.lastname: Drebing
authors.forename: M
authors.initials: M
authors.lastname: Waldo
authors.forename: H
authors.initials: H
authors.lastname: Nagamoto
authors.forename: R
authors.initials: R
authors.lastname: Freedman
mesh_terms: D000328:Adult; D001143:Arousal / Q000502:physiology*; D001288:Attention / Q000502:physiology*; D001714:Bipolar Disorder / Q000503:physiopathology* / Q000523:psychology; D001921:Brain / Q000503:physiopathology; D002395:Catecholamines / Q000097:blood*; D003866:Depressive Disorder / Q000503:physiopathology* / Q000523:psychology; D005072:Evoked Potentials, Auditory / Q000502:physiology*; D005260:Female; D006719:Homovanillic Acid / Q000097:blood; D006801:Humans; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood; D011930:Reaction Time / Q000502:physiology; D012559:Schizophrenia / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D014642:Vanilmandelic Acid / Q000097:blood
chemical_list: D002395:Catecholamines; D008734:Methoxyhydroxyphenylglycol; D014642:Vanilmandelic Acid; D006719:Homovanillic Acid